DAC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Globally, as of 2010, approximately 250 million people had osteoarthritis of the knee (3.6% of the population). Hip osteoarthritis affects about 0.85% of the population. As of 2004, osteoarthritis globally causes moderate to severe disability in 43.4 million people. Together, knee and hip osteoarthritis had a ranking for disability globally of 11th among 291 disease conditions assessed.
RH2 + NAD+ → NADH + H+ + R; From the electron pair of the hydride ion, one electron is attracted to the slightly more electronegative atom of the nicotinamide ring of NAD+, becoming part of the nicotinamide moiety. The remaining hydrogen atom is transferred to the carbon atom opposite the N atom. The midpoint potential of the NAD+/NADH redox pair is −0.32 volts, which makes NADH a moderately strong reducing agent. The reaction is easily reversible, when NADH reduces another molecule and is re-oxidized to NAD+. This means the coenzyme can continuously cycle between the NAD+ and NADH forms without being consumed. In appearance, all forms of this coenzyme are white amorphous powders that are hygroscopic and highly water-soluble. The solids are stable if stored dry and in the dark. Solutions of NAD+ are colorless and stable for about a week at 4 °C and neutral pH, but decompose rapidly in acidic or alkaline solutions. Upon decomposition, they form products that are enzyme inhibitors.
=== Dantrolene === Dantrolene is a muscle relaxant that appears to work directly on the ryanodine receptor to prevent the release of calcium. After the widespread introduction of treatment with dantrolene, the mortality of malignant hyperthermia fell from 80% in the 1960s to less than 5%. Dantrolene remains the only drug known to be effective in the treatment of MH. The recommended dose of dantrolene is 2.5 mg/kg, repeated as necessary. It is recommended that each hospital keeps a minimum stock of 36 dantrolene vials (720 mg), sufficient for four doses in a 70-kg person.
The political aim was to discredit the Japanese-sponsored republic and build the concept of a functioning democracy as a grass roots level, while the economic objective was to prevent the enemy's looting. The result was the creation of the Central Luzon Bureau (CLB), an organization meant to lead resistance against the Japanese. Key positions were filled out as follows:
Selenoprotein I (SELENOI/EPT1), a CDP-ethanolamine:diacylglycerol ethanolamine-phosphotransferase. Selenoprotein K and Selenoprotein S are small transmembrane proteins found on the ER menbrane. Selenoprotein M and Selenoprotein F, thioredoxin-like proteins found in the endoplasmic reticulum (ER). Selenoprotein N, a large transmembran proteins found on the ER menbrane. Selenoprotein O, protein found in the mitochondrial, probably with a redox function. Selenoprotein P is an extracellular glycoprotein, unusually with more than one Sec residue (usually several), found in eukaryotes including humans. The precise number of residues vary and appears linked to the selenium needs of the organism. Selenoprotein R (MSRB1) is a peptide-methionine (R)-S-oxide reductase. It has two non-selenoprotein relatives in humans, also of the same catalytic activity. Families only existing as non-seleno-proteins in mammals:
Sources: en.wikipedia.org
Per a 1970 paper reporting the parent cation's isolation, "Simple mixing of 3-chlorocyclopropene with antimony pentachloride, aluminum trichloride, or silver fluoroborate...[leads] to the salts of cyclopropenyl cation." The hexachloroantimonate (SbCl−6) salt is indefinitely stable at −20 °C. Trichlorocyclopropenium salts are generated by chloride abstraction from tetrachlorocyclopropene:
Dolichonychia is a medical condition in which the nail beds of the fingers and toes are abnormally long and slender, specifically, a finger nail index of 1.30 or more, it is a common feature in people with connective tissue disorders, such as Ehlers–Danlos syndromes, Marfan syndrome, and hypohidrotic ectodermal dysplasia., it often appears alongside arachnodactyly and/or dolichostenomelia, which is the condition of having long and slender fingers and toes.
== History == The earliest description of a lectin is believed to have been given by Peter Hermann Stillmark in his doctoral thesis presented in 1888 to the Imperial University of Dorpat. Stillmark isolated ricin, an extremely toxic hemagglutinin, from seeds of the castor plant (Ricinus communis). Although lectins were first discovered in plants, they are now known to be present throughout nature. The first lectin to be purified on a large scale and available on a commercial basis was concanavalin A, which is now the most-used lectin for characterization and purification of sugar-containing molecules and cellular structures. The legume lectins are probably the most well-studied lectins. Long before a deeper understanding of their numerous biological functions was developed, the plant lectins, also known as phytohemagglutinins, were noted for their particularly high specificity for foreign glycoconjugates (e.g., those of fungi and animals) and used in biomedicine for blood cell testing and in biochemistry for fractionation.
== Non-invasive techniques == Noninvasive neuromodulation encompasses several electroceutical techniques: Acoustic photonic intellectual neurostimulation (APIN); Light therapy (LT); Photobiomodulation (PBM); Low-frequency sound stimulations, including Vibroacoustic therapy (VAT) and Rhythmic auditory stimulation (RAS); a group of transcranial electrical and magnetic methods: Transcranial magnetic stimulation (TMS), Repetitive transcranial magnetic stimulation (rTMS), Transcranial pulsed electromagnetic fields (tPEMF), Transcranial direct current stimulation (tDCS), Transcranial alternating current stimulation (tACS), Transcranial pulsed current stimulation (tPCS), Transcranial random noise stimulation (tRNS), Transcutaneous electrical nerve stimulation (TENS). The general principle of these noninvasive techniques is that they exert their functions through inducing mitochondrial stress.
Sources: en.wikipedia.org
Aortic dissection (AD) occurs when an injury to the innermost layer of the aorta allows blood to flow between the layers of the aortic wall, forcing the layers apart. In most cases, this is associated with a sudden onset of agonizing chest or back pain, often described as "tearing" in character. Vomiting, sweating, and lightheadedness may also occur. Damage to other organs may result from the decreased blood supply, such as stroke, lower extremity ischemia, or mesenteric ischemia. Aortic dissection can quickly lead to death from insufficient blood flow to the heart or complete rupture of the aorta. AD is more common in those with a history of high blood pressure; a number of connective tissue diseases that affect blood vessel wall strength including Marfan syndrome and Ehlers–Danlos syndrome; a bicuspid aortic valve; and previous heart surgery. Major trauma, smoking, cocaine use, pregnancy, a thoracic aortic aneurysm, inflammation of arteries, and abnormal lipid levels are also associated with an increased risk. The diagnosis is suspected based on symptoms with medical imaging, such as CT scan, MRI, or ultrasound used to confirm and further evaluate the dissection. The two main types are Stanford type A, which involves the first part of the aorta, and type B, which does not. Prevention is by blood pressure control and smoking cessation. Management of AD depends on the part of the aorta involved. Dissections that involve the first part of the aorta (adjacent to the heart) usually require surgery.
=== Peak phase === The positive feedback of the rising phase slows and comes to a halt as the sodium ion channels become maximally open. At the peak of the action potential, the sodium permeability is maximized and the membrane voltage Vm is nearly equal to the sodium equilibrium voltage ENa. However, the same raised voltage that opened the sodium channels initially also slowly shuts them off, by closing their pores; the sodium channels become inactivated. This lowers the membrane's permeability to sodium relative to potassium, driving the membrane voltage back towards the resting value. At the same time, the raised voltage opens voltage-sensitive potassium channels; the increase in the membrane's potassium permeability drives Vm towards EK. Combined, these changes in sodium and potassium permeability cause Vm to drop quickly, repolarizing the membrane and producing the "falling phase" of the action potential.
Djalikatou Diallo- former vice-president Guinean Football Federation, former vice-president Nation Assembly, former Minister of National unity and Citizenship. Diaka Sidibé- former Minister of Higher Education, Scientific Research and Innovation, former Minister of Trade, Industry and Small and Medium-sized Enterprises. Kadiatou Émilie Diaby - former Minister of Public Works. Ibrahima Abé Sylla - Minister of Energy, Hydropower and Hydrocarbons, Guinea. Aïssatou Bobo Baldé - former vice president National Assembly. Barry Diawadou – Civil clerk and politician, former member of the French National Assembly and former Minister of Education. Guinea Mamoudou Nagnalen Barry - former minister of Agriculture. Sidibé Fatoumata Kaba (diplomat) - former minister of foreign affairs, former permanent Representative to the African union And The United Nations, former ambassador to Nigeria, Ethiopia. Ambassador to the united states, Guinea. Mama Kanny Diallo - Economist, former Minister of Planning and Economic Development, Guinea. Saifoulaye Diallo –Politician and lawmaker, former member of the French National Assembly, former president of the Territorial Assembly and President of the National Assembly; former Minister of State (foreign affairs, finance, social services). Elhadj Gando Barry - former Minister of Infrastructure and Public Works, CEO Électricité de Guinée. Ibrahima Barry (popularly known as Barry III) – Lawyer and politician, former Minister from Guinea Oumar Diouhé Bah - Minister of Health and public hygiene, Guinea.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.